Download pdf
Progress in the treatment of dementia with astragaloside
- 1 Graduate School of Heilongjiang Academy of Traditional Chinese Medicine
- 2 Zhengzhou Research Institute, Harbin Institute of Technology, Harbin, China
- 3 School of Medicine and Health, Harbin Institute of Technology
* Author to whom correspondence should be addressed.
Abstract
Astragaloside, as a traditional Chinese medicine ingredient, has received widespread attention for its application in dementia treatment. In this paper, we reviewed the neuroprotective effects of astragaloside in the treatment of Alzheimer's disease, Parkinson's disease, vascular dementia, and many other diseases related to cognitive function. It was shown that astragaloside effectively improved the cognitive dysfunction under these conditions through multiple mechanisms such as antioxidant, anti-inflammatory and promotion of neuronal survival. In this paper, we hope that the summarization of the current domestic and international studies will help develop more effective treatment options for dementia and also provide new opportunities for the application of traditional Chinese medicine in modern medicine. With future research, the potential of astragaloside in the treatment of dementia will be more fully demonstrated, providing more therapeutic options for an aging society.
Keywords
Astragaloside, dementia, cognitive impairment
[1]. National Medical Journal of China. (2018). 2018 Chinese guidelines for diagnosis and treatment of dementia and cognitive impairment (I): Dementia and its diagnostic criteria for classification. National Medical Journal of China, 98(13), 965-970.
[2]. Yao, M., Zhang, L., & Wang, L. (2023). Astragaloside IV: A promising natural neuroprotective agent for neurological disorders. Biomedicine & Pharmacotherapy, 159, 114229.
[3]. Hugo, J., & Ganguli, M. (2014). Dementia and cognitive impairment. Clinics in Geriatric Medicine, 30(3), 421-442.
[4]. Lane, C. A., Hardy, J., & Schott, J. M. (2018). Alzheimer’s disease. European Journal of Neurology, 25(1), 59-70.
[5]. Li, E. L., & Li, Z. G. (2024). Research progress on the correlation between mitochondrial dysfunction and Alzheimer's disease. World Science and Technology - Modernization of Traditional Chinese Medicine, 12, 3025-3033.
[6]. Bao, M., Bade, R., Liu, H. (2023). Astragaloside IV against Alzheimer’s disease via microglia-mediated neuroinflammation using network pharmacology and experimental validation. European Journal of Pharmacology, 957, 175992.
[7]. F, C., D, Y., XY, C. (2021). Astragaloside IV ameliorates cognitive impairment and neuroinflammation in an oligomeric Aβ induced Alzheimer’s disease mouse model via inhibition of microglial activation and NADPH oxidase expression. Biological & Pharmaceutical Bulletin, 44(11).
[8]. Wang, X. (2017). Astragaloside IV, a natural PPARγ agonist, reduces Aβ production in Alzheimer’s disease through inhibition of BACE1. Molecular Neurobiology.
[9]. Li, K. L., Zhou, Y. T., Li, Y. R. (2023). Research progress on the mechanism of action of Astragaloside in treating central nervous system diseases. Traditional Chinese Medicine, 45(8), 2634-2641.
[10]. Costa, I. M., Lima, F. O. V., Fernandes, L. C. B. (2019). Astragaloside IV supplementation promotes a neuroprotective effect in experimental models of neurological disorders: A systematic review. Current Neuropharmacology, 17(7), 648-665.
[11]. Sun, Q., Jia, N., Wang, W. (2014). Protective effects of Astragaloside IV against amyloid Beta1-42 neurotoxicity by inhibiting the mitochondrial permeability transition pore opening. PLOS ONE, 9(6).
[12]. Hayashi, Y. (2020). Effects of neural stem cell transplantation in Alzheimer’s disease models. Journal of Biomedical Science, 27(1), 29.
[13]. Wang, X., Gao, F., Xu, W. (2023). Deciphering the effects of Astragaloside IV on AD-like phenotypes: A systematic and experimental investigation. Oxidative Medicine and Cellular Longevity, 2021(1)
[14]. Kumar, S., Goyal, L., & Singh, S. (2022). Tremor and rigidity in patients with Parkinson’s disease: Emphasis on epidemiology, pathophysiology and contributing factors. CNS & Neurological Disorders Drug Targets, 21(7), 596-609.
[15]. Cui, X. M., Wang, Y. L., Han, B. (2014). Excitotoxicity in Parkinson's disease and hepatocyte growth factor. Chinese Journal of Practical Neurological Diseases, 17(4), 102-103.
[16]. Zhang, C. Y., Zhu, X. Y., Zhai, T. (2024). Research progress on the mechanism of Astragalus in the treatment of Parkinson's disease. West China Journal of Pharmaceutical Sciences, 39(5), 611-616.
[17]. Tansey, M. G., Wallings, R. L., Houser, M. C. (2022). Inflammation and immune dysfunction in Parkinson disease. Nature Reviews Immunology, 22(11), 657-673.
[18]. Xu, Z., Yang, D., Huang, X. (2021). Astragaloside IV protects 6-hydroxydopamine-induced SH-SY5Y cell model of Parkinson’s disease via activating the JAK2/STAT3 pathway. Frontiers in Neuroscience, 15, 631501.
[19]. Xia, L., Guo, D., & Chen, B. (2017). Neuroprotective effects of astragaloside IV on Parkinson disease models of mice and primary astrocytes. Experimental and Therapeutic Medicine, 14(6), 5569-5575.
[20]. Zhang, T. Q., Li, C. C., Zhang, T. F. (2021). [Mechanism of astragaloside Ⅳ alleviating PC12 cell injury by activating PI3K/AKT signaling pathway: Based on network pharmacology and in vitro experiments]. Zhongguo Zhong Yao Za Zhi, 46(24), 6465-6473.
[21]. Ge, B., Li, S. L., & Li, F. R. (2020). Astragaloside-IV regulates endoplasmic reticulum stress-mediated neuronal apoptosis in a murine model of Parkinson’s disease via the lincRNA-p21/CHOP pathway. Experimental and Molecular Pathology, 115, 104478. https://doi.org/10.1016/j.yexmp.2020.104478
[22]. Dehay, B., Martinez-Vicente, M., Caldwell, G. A. (2013). Lysosomal impairment in Parkinson’s disease. Movement Disorders, 28(6), 725-732.
[23]. Xia, M. L., Xie, X. H., Ding, J. H. (2020). Astragaloside IV inhibits astrocyte senescence: Implication in Parkinson’s disease. Journal of Neuroinflammation, 17, 105.
[24]. Liu, Y., Chong, L., Li, X. (2017). Astragaloside IV rescues MPP+-induced mitochondrial dysfunction through upregulation of methionine sulfoxide reductase A. Experimental and Therapeutic Medicine, 14(3), 2650-2656.
[25]. Yang, C., Mo, Y., Xu, E. (2019). Astragaloside IV ameliorates motor deficits and dopaminergic neuron degeneration via inhibiting neuroinflammation and oxidative stress in a Parkinson’s disease mouse model. International Immunopharmacology, 75, 105651.
[26]. Ma, Q., Tang, M. K., & Sun, W. Y. (2018). Modern research summary on the pathogenesis of vascular dementia from the perspective of traditional Chinese medicine. Chinese Journal of Traditional Chinese Medicine and Pharmacy, 33(1), 212-215.
[27]. Huang, X. P., Ding, H., Wang, B. (2015). Effects of the main active components combinations of Astragalus and Panax notoginseng on energy metabolism in brain tissues after cerebral ischemia-reperfusion in mice. Pharmacognosy Magazine, 11(44), 732.
[28]. Xue, B., Huang, J., Ma, B. (2019). Astragaloside IV protects primary cerebral cortical neurons from oxygen and glucose deprivation/reoxygenation by activating the PKA/CREB pathway. Neuroscience, 404, 326-337.
[29]. Yang, J. (2021). Protective effects of Astragaloside IV against oxidative injury and apoptosis in cultured astrocytes by regulating Nrf2/JNK signaling. Experimental Brain Research.
[30]. Tang, B., Tang, W. J., Tang, Y. H. (2019). Astragaloside alleviates cerebral ischemia-reperfusion injury in rats and inhibits NF-κB phosphorylation and NLRP3 inflammasome activation. Acta Physiologica Sinica, 71(3), 424-430.
[31]. Yin, F., Zhou, H., Fang, Y. (2020). Astragaloside IV alleviates ischemia reperfusion-induced apoptosis by inhibiting the activation of key factors in death receptor pathway and mitochondrial pathway. Journal of Ethnopharmacology, 248, 112319.
[32]. Li, M. (2013). Astragaloside IV reduces cerebral edema post-ischemia/reperfusion correlating the suppression of MMP-9 and AQP4. European Journal of Pharmacology.
[33]. Li, L., Gan, H., Jin, H. (2021). Astragaloside IV promotes microglia/macrophages M2 polarization and enhances neurogenesis and angiogenesis through PPARγ pathway after cerebral ischemia/reperfusion injury in rats. International Immunopharmacology, 92, 107335.
[34]. Sun, L., Wang, L., Li, Y. (2014). Protective effects and mechanisms of Astragaloside on cerebral ischemia reperfusion injury in rats. Chinese Journal of Clinical Neuroscience, 22(1), 43-49.
[35]. Li, P. T., Gao, Z. H., Duan, X. L. (2018). Experimental study on differentiation of SAMR1 mouse bone marrow mesenchymal stem cells into neurons induced by Astragaloside IV. Journal of Hebei Medical University, 39(11), 1338-1343.
[36]. Chen, X. (2019). Astragaloside VI promotes neural stem cell proliferation and enhances neurological function recovery in transient cerebral ischemic injury via activating EGFR/MAPK signaling cascades. Molecular Neurobiology.
[37]. Ni, G. X., Liang, C., Wang, J. (2020). Astragaloside IV improves neurobehavior and promotes hippocampal neurogenesis in MCAO rats though BDNF-TrkB signaling pathway. Biomedicine & Pharmacotherapy, 130, 110353.
[38]. Gan, H. X. (2022). Mechanism study on Astragaloside-mediated RhoA pathway promotion of neurite outgrowth [Doctoral dissertation, Hubei University for Nationalities].
[39]. Wang, L., Liu, C., Wang, L., Tang, B. (2023). Astragaloside IV mitigates cerebral ischaemia-reperfusion injury via inhibition of P62/Keap1/Nrf2 pathway-mediated ferroptosis. European Journal of Pharmacology, 944, 175516.
[40]. Oyefeso, F. A., Goldberg, G., Opoku, N. Y. P. S. (2023). Effects of acute low-moderate dose ionizing radiation to human brain organoids. PLOS ONE, 18(5), e0282958.
[41]. Kempf, S. J., Azimzadeh, O., Atkinson, M. J. (2013). Long-term effects of ionising radiation on the brain: Cause for concern? Radiation and Environmental Biophysics. 52(2013), 5-16.
[42]. Liu, X., Ding, Y., Jiang, C. (2024). Astragaloside IV mediates radiation-induced neuronal damage through activation of BDNF-TrkB signaling. Phytomedicine, 132, 155803.
[43]. Ding, Y., Jiang, C., Chen, L. (2025). Astragaloside IV confers neuroprotection against radiation-induced neuronal senescence via the ERK pathway. Experimental Neurology, 386, 115135.
[44]. Liu, X., Chu, W., Shang, S. (2020). Preliminary study on the anti-apoptotic mechanism of Astragaloside IV on radiation-induced brain cells. International Journal of Immunopathology and Pharmacology, 34, 2058738420954594.
[45]. Zhang, Y., Yuan, Y., Zhang, J. (2022). Astragaloside IV supplementation attenuates cognitive impairment by inhibiting neuroinflammation and oxidative stress in type 2 diabetic mice. Frontiers in Aging Neuroscience, 14.
[46]. Zhang, R., Cao, S., Shi, Y. (2023). Astragaloside IV-mediated inhibition of oxidative stress by upregulation of ghrelin in type 2 diabetes–induced cognitive impairment. Naunyn-Schmiedeberg's Archives of Pharmacology, 396(10), 2637-2650.
[47]. Zhao, J., Zhao, G., Lang, J. (2024). Astragaloside IV ameliorated neuroinflammation and improved neurological functions in mice exposed to traumatic brain injury by modulating the PERK-eIF2α-ATF4 signaling pathway. Journal of Investigative Medicine, 72(7), 747-762.
[48]. Z, W., Z, L., Y, T. (2024). Astragaloside IV alleviates heatstroke brain injury and neuroinflammation in male mice by regulating microglial polarization via the PI3K/Akt signaling pathway. Biomedicine & Pharmacotherapy, 180.
[49]. Yu, C., Pan, S., Dong, M. (2017). Astragaloside IV attenuates lead acetate-induced inhibition of neurite outgrowth through activation of Akt-dependent Nrf2 pathway in vitro. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1863(6), 1195-1203.
[50]. Y, L., Y, Z., C, N. (2019). Astragaloside IV and ferulic acid synergistically promote neurite outgrowth through Nrf2 activation. Mechanisms of Ageing and Development, 180.
[51]. Yu, C., Zhang, J., Li, X. (2021). Astragaloside IV-induced Nrf2 nuclear translocation ameliorates lead-related cognitive impairments in mice. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1868(1), 118853.
Cite this article
Chen,Z.;Baranenko,D.;Lu,W. (2025). Progress in the treatment of dementia with astragaloside. Journal of Clinical Technology and Theory,3(1),39-44.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Journal：Journal of Clinical Technology and Theory
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).